2010
Preterm birth results in alterations in neural connectivity at age 16 years
Mullen KM, Vohr BR, Katz KH, Schneider KC, Lacadie C, Hampson M, Makuch RW, Reiss AL, Constable RT, Ment LR. Preterm birth results in alterations in neural connectivity at age 16 years. NeuroImage 2010, 54: 2563-2570. PMID: 21073965, PMCID: PMC3020252, DOI: 10.1016/j.neuroimage.2010.11.019.Peer-Reviewed Original ResearchConceptsDiffusion tensor imagingAge 16 yearsPT subjectsBrain injuryLow birth weight preterm childrenTerm controlsUncinate fasciculusBilateral external capsuleFA valuesWeight preterm childrenNeonatal brain injuryLower fractional anisotropy valuesYears of ageBilateral uncinate fasciculusFractional anisotropy valuesRight uncinate fasciculusRight arcuate fasciculusWhite matter disorganizationAlternative neural pathwaysPreterm birthExternal capsuleInferior frontal gyrusPreterm childrenCorpus callosumHigh riskFunctional connectivity to a right hemisphere language center in prematurely born adolescents
Myers EH, Hampson M, Vohr B, Lacadie C, Frost SJ, Pugh KR, Katz KH, Schneider KC, Makuch RW, Constable RT, Ment LR. Functional connectivity to a right hemisphere language center in prematurely born adolescents. NeuroImage 2010, 51: 1445-1452. PMID: 20347043, PMCID: PMC2872040, DOI: 10.1016/j.neuroimage.2010.03.049.Peer-Reviewed Original ResearchConceptsFunctional connectivityWord Reading EfficiencyVerbal Comprehension IndexWechsler Intelligence ScaleRight supramarginal gyrusPeabody Picture VocabularyGreater cognitive deficitsPPVT-R scoresPhonological processingComprehension IndexLanguage tasksChildren-IIIIntelligence ScaleReading efficiencyLanguage deficitsPicture VocabularyWISC-IIISupramarginal gyrusCognitive outcomesNeurobiological basisHemisphere regionsCognitive deficitsWernicke's areaNeural activityLanguage processing
1993
Low-grade astrocytomas may arise from different astrocyte lineages.
Piepmeier J, Fried I, Makuch R. Low-grade astrocytomas may arise from different astrocyte lineages. Neurosurgery 1993, 33: 627-32. PMID: 8232801, DOI: 10.1227/00006123-199310000-00010.Peer-Reviewed Original ResearchConceptsLow-grade astrocytomasGlial fibrillary acidic protein-positive cellsFibrillary acidic proteinProtein-positive cellsAstrocyte lineagePreoperative symptomsAnti-glial fibrillary acidic proteinAcidic proteinGlial fibrillary acidic proteinLong preoperative historyCommon histological featuresDifferent clinical manifestationsPercentage of cellsPreoperative historyClinical manifestationsHistological featuresImaging featuresRate of proliferationImmunohistochemical analysisAstrocytic phenotypeNeoplastic cellsType 2White matterAstrocytomasTumors
1990
A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy
Roberts R, Hollinger F, Parks W, Rasheed S, Laurence J, Heseltine P, Makuch R, Lubina J, Johnson K, Group R. A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy. AIDS 1990, 4: 67-72. PMID: 1690551, DOI: 10.1097/00002030-199001000-00009.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdolescentAdultAIDS-Related ComplexDouble-Blind MethodFemaleGene Products, gagHIVHIV AntigensHIV Core Protein p24HIV InfectionsHumansMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicRibavirinRibonucleosidesRNA-Directed DNA PolymeraseUnited StatesViral Core ProteinsConceptsOral ribavirinPeripheral blood mononuclear cellsPlacebo-controlled trialBlood mononuclear cellsMulticenter clinical trialHIV isolationP24 antigenemiaStudy drugMulticenter trialActive treatmentDaily dosesMononuclear cellsClinical trialsMedical CenterWeek 6HIV activityAdult menRibavirinTrialsLymphadenopathyHIVInterlaboratory variationCritical roleAntigenemiaPlaceboA multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group.
Roberts R, Dickinson G, Heseltine P, Leedom J, Mansell P, Rodriguez S, Johnson K, Lubina J, Makuch R. A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1990, 3: 884-92. PMID: 1974628.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdministration, OralAdolescentAdultCD4 AntigensCD4-Positive T-LymphocytesDose-Response Relationship, DrugDouble-Blind MethodEvaluation Studies as TopicHumansImmunoblastic LymphadenopathyLeukocyte CountMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicRibavirinRibonucleosidesConceptsOral ribavirinActive treatmentBaseline CD4 cell countMajor protocol violationsCD4 cell countPlacebo-controlled trialMulticenter clinical trialSignificant differencesPlacebo patientsPlacebo groupPlacebo treatmentStudy entryTreat analysisWashout periodDaily dosesClinical trialsKaposi's sarcomaProtocol violationsMedical CenterTreatment superiorityTreatment groupsPlaceboRibavirinPatientsOverall significant difference
1989
Goodman and Kruskal's λ: A new look at an old measure of association
Makuch R, Rosenberg P, Scott G. Goodman and Kruskal's λ: A new look at an old measure of association. Statistics In Medicine 1989, 8: 619-631. PMID: 2727480, DOI: 10.1002/sim.4780080511.Peer-Reviewed Original Research
1988
A prospective randomized trial of HLA‐matched versus mismatched single‐donor platelet transfusions in cancer patients
Messerschmidt G, Makuch R, Appelbaum F, Ungerleider R, Abrams R, O'Donnell J, Holohan T, Fontana J, Wright D, Anagnou N, Shan T, Chesbro B, Deisseroth A. A prospective randomized trial of HLA‐matched versus mismatched single‐donor platelet transfusions in cancer patients. Cancer 1988, 62: 795-801. PMID: 3293762, DOI: 10.1002/1097-0142(19880815)62:4<795::aid-cncr2820620426>3.0.co;2-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAmbulatory CareAntibody FormationBlood DonorsBlood PlateletsBlood TransfusionChildChild, PreschoolClinical Trials as TopicFemaleHemorrhageHistocompatibility TestingHumansInfantMaleMiddle AgedNeoplasmsPlatelet TransfusionProspective StudiesRandom AllocationThrombocytopeniaTransfusion ReactionConceptsSingle-donor platelet transfusionsPlatelet transfusionsCancer patientsFebrile patientsPosttransfusion incrementsThrombocytopenic cancer patientsTransfusion of HLASevere bleeding episodesMulti-institution trialNonfebrile patientsIntensive chemotherapyBleeding episodesAntiplatelet antibodiesAntibody titersSignificant thrombocytopeniaHistocompatability antigensTransfusionPatientsMismatched groupHLAThrombocytopeniaPlateletsEpisodesSeparate episodesTrials
1985
Effects of fractionated irradiation of endocrine aspects of testicular function.
Shapiro E, Kinsella T, Makuch R, Fraass B, Glatstein E, Rosenberg S, Sherins R. Effects of fractionated irradiation of endocrine aspects of testicular function. Journal Of Clinical Oncology 1985, 3: 1232-9. PMID: 3928830, DOI: 10.1200/jco.1985.3.9.1232.Peer-Reviewed Original ResearchConceptsDose-dependent increaseGerm cell depletionCell depletionTesticular functionBaseline levelsFollicle-stimulating hormone valuesTotal testosterone valuesSerum FSH levelsMedian differenceLeydig cell dysfunctionSoft tissue sarcomasSerum follicle-stimulating hormone (FSH) valuesLeydig cell functionHigh-dose radiationLH changesTubule injuryFSH levelsOnly patientsSerum FSHLH concentrationsTesticular doseHormonal alterationsHormone valuesTumor bedRadiation injuryPrognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival
Ihde D, Matthews M, Makuch R, McIntire K, Eddy J, Seeff L. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival. The American Journal Of Medicine 1985, 78: 399-406. PMID: 2579551, DOI: 10.1016/0002-9343(85)90330-4.Peer-Reviewed Original ResearchConceptsAlpha-fetoprotein levelsFibrolamellar carcinomaHepatocellular carcinomaSystemic chemotherapyNormal serum alpha-fetoprotein levelsHepatitis B serum markersNormal alpha-fetoprotein levelsSerum alpha-fetoprotein levelsElevated alpha-fetoprotein levelsAmbulatory performance statusHomogeneous clinical featuresAbsence of cirrhosisHepatitis B markersTime of diagnosisGroup of patientsInitiation of treatmentLack of jaundiceAmbulatory statusExtrahepatic metastasesPerformance statusImproved survivalIndolent coursePrognostic factorsClinical featuresSerum markers
1984
Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience.
Tester W, Kinsella T, Waller B, Makuch R, Kelley P, Glatstein E, DeVita V. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. Journal Of Clinical Oncology 1984, 2: 762-9. PMID: 6547479, DOI: 10.1200/jco.1984.2.7.762.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsHodgkin's diseaseMalignant neoplasmsSolid tumorsNational Cancer Institute ExperienceChronic myeloid leukemiaCases of sarcomaRisk of leukemiaUntreated patientsPatient ageHodgkin's lymphomaMedical recordsInstitute experienceMyeloid leukemiaSimilar riskAge 40Treatment groupsPatientsGreater riskLeukemiaTen yearsDiseaseTumorsLymphomaPositive association
1983
Intensive combined modality therapy including low-dose TBI in high-risk ewing's sarcoma patients
Kinsella T, Glaubiger D, Diesseroth A, Makuch R, Waller B, Pizzo P, Glatstein E. Intensive combined modality therapy including low-dose TBI in high-risk ewing's sarcoma patients. International Journal Of Radiation Oncology • Biology • Physics 1983, 9: 1955-1960. PMID: 9463099, DOI: 10.1016/0360-3016(83)90368-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgranulocytosisAntineoplastic Combined Chemotherapy ProtocolsBone Marrow TransplantationBone NeoplasmsChildCombined Modality TherapyCyclophosphamideDactinomycinDisease-Free SurvivalFemaleHumansLung NeoplasmsMaleNeoplasm Recurrence, LocalSarcoma, EwingVincristineWhole-Body IrradiationConceptsAutologous bone marrow infusionHigh-risk Ewing's sarcoma patientsTotal body irradiationEwing's sarcoma patientsLow-dose total body irradiationComplete clinical responseSarcoma patientsGranulocyte recoveryClinical responseModality therapyModality protocolMedian disease-free intervalMicroscopic systemic diseaseMonths of relapseBone marrow infusionCells/mm3Disease-free intervalPoor prognosis groupOnly distant metastasesTotal granulocyte countConsolidative therapyInduction therapyInitial relapseMaintenance chemotherapySecond relapse
1979
EFFECTS OF THYMOSIN IN VITRO IN CANCER PATIENTS AND CORRELATION WITH CLINICAL COURSE AFTER THYMOSIN IMMUNOTHERAPY
Chretien P, Lipson S, Makuch R, Kenady D, Cohen M. EFFECTS OF THYMOSIN IN VITRO IN CANCER PATIENTS AND CORRELATION WITH CLINICAL COURSE AFTER THYMOSIN IMMUNOTHERAPY. Annals Of The New York Academy Of Sciences 1979, 332: 135-147. PMID: 316979, DOI: 10.1111/j.1749-6632.1979.tb47107.x.Peer-Reviewed Original ResearchSerum glycoproteins and immunoglobulins in nasopharyngeal carcinoma Correlations with Epstein-Barr virus associated antibodies and clinical tumor stage
Baskies A, Chretien P, Yang C, Wolf G, Makuch R, Tu S, Hsu M, Lynn T, Yang H, Weiss J, Spiegel H. Serum glycoproteins and immunoglobulins in nasopharyngeal carcinoma Correlations with Epstein-Barr virus associated antibodies and clinical tumor stage. The American Journal Of Surgery 1979, 138: 478-488. PMID: 225960, DOI: 10.1016/0002-9610(79)90406-9.Peer-Reviewed Original ResearchConceptsClinical tumor stageElevated antibody titersEpstein-Barr virusSerum levelsAntibody titersTumor stageAcute phase proteinsNasopharyngeal carcinomaTumor presenceImmunoglobulin levelsNormal subjectsEBV antibody titersSerum haptoglobin levelsNeck squamous carcinomaHealthy normal subjectsMonitoring of responseSerum glycoproteinsAnti-EBVUntreated patientsIgA antibodiesEarly antigenSquamous carcinomaStaging systemImmunoglobulins IgAHaptoglobin levelsAbnormalities of Zinc and Copper During Total Parenteral Nutrition
LOWRY S, GOODGAME J, SMITH J, MAHER M, MAKUCH R, HENKIN R, BRENNAN M. Abnormalities of Zinc and Copper During Total Parenteral Nutrition. Annals Of Surgery 1979, 189: 120. PMID: 103506, PMCID: PMC1396940, DOI: 10.1097/00000658-197901000-00023.Peer-Reviewed Original ResearchConceptsParenteral nutritionSerum zincSerum levelsLimited oral intakeTotal parenteral nutritionMean serum zincNormal serum levelsSupplementation of zincCopper levelsPositive nitrogen retentionOral intakeUrinary outputBlood administrationUrinary nitrogen excretionHyperalimentation fluidsNormal limitsUrinary zincPatientsCopper excretionCopper intakeCopper supplementationExcretionNutritionIntakeSupplementation